Gland Pharma Share Surges Over 4% After USFDA Approves Sugammadex Injection Single-Dose Vials

Gland Pharma Ltd. has received approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Sugammadex Injection 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vials, as per the exchange filings.  

The company has also launched the product in the US through its marketing partner.  

Approval Covers Two Single-Dose Vial Presentations 

The approved product is bioequivalent and therapeutically equivalent to BRIDION Injection of Merck Sharp & Dohme LLC.  

It is indicated for the reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide in adult and pediatric patients undergoing surgery.  

Reference Market Recorded $1.6 Billion in Sales 

Gland Pharma said it has commercially launched the product on Day 1 through its marketing partner following the USFDA approval. 

According to IQVIA, the reference product recorded approximately $1.6 billion in US sales during the 12 months ended April 2026, indicating the size of the addressable market.  

Read More: CarTrade Tech Partners with Spinny to Transform Used Car Buying and Selling! 

Gland Pharma Share Price Performance 

As of July 29, 2026, at 2:35 PM, Gland Pharma share price was trading at ₹2,539 per share, reflecting a surge of 4.56% from the previous trading session. 

Conclusion 

Gland Pharma has received USFDA approval for Sugammadex Injection in two single-dose vial presentations and has commenced the product's commercial launch in the US through its marketing partner. 

Want to read stock market updates in Hindi? Angel One News gives comprehensive share market news in Hindi.  

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.  

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.